FDA has cleared the Simplexa Flu A/B and RSV Direct Gen II kit from DiaSorin Molecular, Cypress, Calif. The Simplexa Flu A/B & RSV Direct Gen II assay can be run alone or alongside the Simplexa Covid-19 Direct kit to allow for differential diagnosis of SARS-CoV-2, influenza A (Flu A), influenza B (Flu B), and respiratory syncytial virus (RSV). The upcoming 2020/2021 flu season will be complicated by the presence of SARS-CoV-2 also circulating in the community. Viral infections caused by Flu A, Flu B, RSV, and SARS-CoV-2 have similar clinical presentations. However, treatment options are different and thus it is important to differentiate. Additionally, co-infection with SARS-CoV-2 and Flu A or B has been shown to cause increased severity of respiratory disease and the need for a combination therapy. The accurate diagnosis of the virus causing the infection can have major implications for the management of therapeutic regimens, infection control, and community mitigation efforts. DiaSorin Molecular’s latest generation Simplexa Flu A/B & RSV Direct Gen II kit delivers continued comprehensive strain coverage and accurate detection in an efficient and trusted sample-to-answer format that does not require extraction. Collectively, over 100 Flu A, Flu B, and RSV strains have been validated, including the 2020/2021 influenza vaccine strains. The Simplexa Flu A/B & RSV Direct Gen II assay is designed for use with the Liaison MDX instrument. “With covid-19 set to play a major role in the upcoming flu season, it was critical for us to have the Simplexa Flu A/B & RSV Direct Gen II assay available in time for patient samples to be tested, when needed, alongside the Simplexa COVID-19 Direct assay,” says Michelle Tabb, chief scientific officer of DiaSorin Molecular. “Detection and differential diagnosis between influenza, RSV, and covid-19 will be vital this year and we are pleased to contribute to this solution.” The Simplexa Covid-19 Direct kit received FDA emergency use authorization for use by authorized laboratories. For more information, visit DiaSorin Molecular.
FDA Says COVID-19 Antigen Tests May be Less Sensitive to Omicron Variant, but They’re Still an Important Tool
December 30, 2021
Cue Applies for EUA for Flu + COVID-19 Molecular Test
October 4, 2022
Immunoassay Developer Calbiotech Merges with Moduline Systems
December 16, 2013